ABVC BioPharma Inc
ABVC
Company Profile
Business description
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
Contact
44370 Old Warm Springs Boulevard
FremontCA94538
USAT: +1 510 668-0881
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
19
Stocks News & Analysis
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
With recent structural changes and strong Azure performance, here’s what we think of Microsoft stock.
stocks
Tesla earnings: Shares fall as market focuses on uncertainty in near term
Are shares overpriced despite the fall?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,321.60 | 22.10 | -0.24% |
| CAC 40 | 8,225.78 | 18.91 | 0.23% |
| DAX 40 | 24,207.79 | 56.66 | 0.23% |
| Dow JONES (US) | 46,734.61 | 144.20 | 0.31% |
| FTSE 100 | 9,578.57 | 63.57 | 0.67% |
| HKSE | 26,141.43 | 173.45 | 0.67% |
| NASDAQ | 22,941.80 | 201.40 | 0.89% |
| Nikkei 225 | 49,230.51 | 588.90 | 1.21% |
| NZX 50 Index | 13,412.67 | 35.57 | 0.27% |
| S&P 500 | 6,738.44 | 39.04 | 0.58% |
| S&P/ASX 200 | 9,022.90 | 21.30 | -0.24% |
| SSE Composite Index | 3,941.39 | 18.98 | 0.48% |